Predicting role of molecular gene marker in targeted therapy of non-small-cell lung cancer / 肿瘤研究与临床
Cancer Research and Clinic
;
(6): 295-298, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-383889
ABSTRACT
After many targeted drugs have entered into the treatment guideline or all stage clinical trial of non-small-cell lung cancer (NSCLC), many researchers undertake deep investigation on the role of molecular gene marker in targeted therapy of NSCLC. It is a good outset that mutation detection of epidermal growth factor receptor (EGFR) gene direct the selection of EFGR tyrosine kinase inhibitors (EGFR-TKI). To choose individualized therapy regimens according to molecular gene marker will be the important research direction, but also be the critical measure to improve the management level of NSCLC and prolong patient"s survival. Accompanied with deep investigation of targeted therapy, there will be more molecular gene markers to direct the formulation of individualized therapy regimens.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Practice guideline
/
Prognostic study
Language:
Chinese
Journal:
Cancer Research and Clinic
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS